Evaluating brain function in patients with multiple brain tumors treated with targeted radiation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the neurocognitive function of patients with multiple brain metastases who are treated with either stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). The study aims to determine if SRS can better preserve neurological function compared to SBRT by assessing cognitive performance at 4 and 12 months post-treatment. Participants will undergo a series of neurocognitive tests and quality of life assessments, alongside monitoring for symptom burden and survival outcomes. The trial includes a follow-up period to evaluate the long-term effects of the treatments on brain function and overall health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically proven solid tumor malignancy (except for small cell lung cancer \[SCLC\], germ cell tumor)
* Karnofsky performance status \>= 60
* 1 to 10 brain metastases (mets) (no more than two lesions and/or cavities \>= 3 cm in maximum diameter)
* Maximum diameter of brain metastasis or resection cavity is 6 cm
* Serum creatinine =\< 3 mg/dL and creatinine clearance \>= 30 ml/min
* Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up; patients must be willing to complete neurocognitive assessments at pre-specified time points outlined in the protocol
* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose
* Patient able to provide his/her own written informed consent and speak English

Exclusion Criteria:

* Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor
* Prior brain surgery =\< 14 days prior to enrollment
* Planned chemotherapy during radiosurgery
* Leptomeningeal metastases
* Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months
* Pregnant women

Where it's running

• Sidney Kimmel Cancer Center at Thomas Jefferson University
  Philadelphia, Pennsylvania, United States Recruiting
• Jefferson Health New Jersey
  Sewell, New Jersey, United States Not yet recruiting

Study contacts

• Principal investigator: Wenyin Shi, MD — Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
• Study coordinator: Wenyin Shi, MD
• Email: wenyin.shi@jefferson.edu
• Phone: (215) 955-6702

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using arginine with whole brain radiation therapy for brain metastases treatment

  This study is testing if taking arginine, either by mouth or through an IV, can help improve the effectiveness of whole brain radiation therapy for people with brain metastases.

  Recruiting Early Phase 1 Emory University · Atlanta, Georgia · NCT06328686

• Comparing single and fractionated stereotactic radiosurgery for brain metastases treatment

  This study is testing whether a single session of targeted radiation or multiple sessions is better for treating patients with brain tumors that have spread from other cancers.

  Recruiting at 6 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 6 other locations · NCT05222620

• Adding targeted GRID-style radiation to standard palliative therapy for unresectable solid tumors

  This study tests whether adding spatially fractionated radiation therapy to standard palliative radiation helps relieve symptoms in patients with unresectable solid tumors.

  Recruiting at 2 sites Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT07856394

• 64Cu-DOTA-Pembrolizumab PET to See If Treatment Is Working in Stage IV NSCLC

  This study tests a new PET imaging agent paired with pembrolizumab to see if it can show which tumors are still responding in adults with stage IV NSCLC who are already receiving pembrolizumab.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07619599

• BMS-986504 plus pemetrexed for MTAP-deleted metastatic solid tumors

  This study tests whether the combination of BMS-986504 and pemetrexed is safe and potentially effective for people with MTAP-deleted metastatic solid tumors.

  Recruiting Phase 1/2 Northwestern University · Chicago, Illinois · NCT07594626

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.